However, targeting HER2 aberrations with conventional anti-HER2 agents has failed to replicate their breast cancer efficacy, indicating the extent of biological diversity conferred by alternative HER2 aberrations, which prevail in distinct malignancies [11,12]. This evidence concerns the gene ERBB2 and breast cancer.